Risk of Serious Bacterial Infection Associated With Tumor Necrosis Factor-Alpha Inhibitors in Children and Young Adults With Inflammatory Bowel Disease

被引:10
作者
Lee, Wan-Ju [1 ]
Lee, Todd A. [1 ,2 ]
Calip, Gregory S. [1 ,2 ]
Suda, Katie J. [1 ,2 ,4 ]
Briars, Leslie [3 ]
Schumock, Glen T. [1 ,2 ]
机构
[1] Univ Illinois, Dept Pharm Syst Outcomes & Policy, Chicago, IL USA
[2] Univ Illinois, Ctr Pharmacoepidemiol & Pharmacoecon Res, Chicago, IL USA
[3] Univ Illinois, Coll Pharm, Dept Pharm Practice, Chicago, IL USA
[4] Hines VA Hosp, Ctr Innovat Complex Chron Healthcare, Hines, IL USA
关键词
biologic therapies; tumor necrosis factor-alpha inhibitors; inflammatory bowel disease; infection; children; young adults; MAINTENANCE INFLIXIMAB THERAPY; PEDIATRIC CROHNS-DISEASE; REPORTED ADVERSE EVENTS; CERTOLIZUMAB PEGOL; ULCERATIVE-COLITIS; SAFETY; METAANALYSIS; ADOLESCENTS; ANTAGONISTS; ADALIMUMAB;
D O I
10.1093/ibd/izx080
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Prior studies evaluating the relationship between tumor necrosis factor-alpha inhibitors (TNFI) and infection were conducted in adults and had conflicting findings. We sought to examine the risk of serious infection associated with TNFIs compared with nonbiologic immunomodulators in children and young adults with inflammatory bowel disease (IBD) and to compare the risk among individual TNFIs. Methods: We conducted a cohort study using the Truven MarketScan Commercial Claims and Encounters database of patients age <30 years with a diagnosis of IBD who initiated treatment with a TNFI or immunomodulator (thiopurines or methotrexate) between 2009 and 2013. The outcome of interest was serious infection, defined as a nongastrointestinal bacterial infection requiring hospitalization. Cox proportional hazard models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for serious infection associated with TNFIs compared with immunomodulators. Results: We identified 10,838 children and young adults with IBD; 236 and 192 cases of serious infection were observed in 4502 TNFI initiators (5.25/100 person-years) and 6336 immunomodulator initiators (3.59/100 person-years), respectively. Compared with immunomodulators, TNFIs were associated with a higher risk of serious infection (HR, 1.36; 95% CI, 1.08-1.72). Among TNFI users, certolizumab showed a 3.38-fold (95% CI, 2.25-5.09) increased risk vs infliximab, and subcutaneously administered TNFIs also exhibited a higher risk (HR, 1.34; 95% CI, 1.18-1.53) than intravenous TNFIs. Conclusions: TNFIs pose a higher risk of serious infection compared with immunomodulators in children and young adults with IBD, and this risk differs among individual TNFIs and routes of administration.
引用
收藏
页码:883 / 891
页数:9
相关论文
共 42 条
[1]  
Alper E., UPTODATE
[2]   Association between tumour necrosis factor-α inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study [J].
Andersen, Nynne Nyboe ;
Pasternak, Bjorn ;
Friis-Moller, Nina ;
Andersson, Mikael ;
Jess, Tine .
BMJ-BRITISH MEDICAL JOURNAL, 2015, 350
[3]  
[Anonymous], 2007, Promoting safety of medicines for children
[4]   Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis [J].
Bonovas, Stefanos ;
Fiorino, Gionata ;
Allocca, Mariangela ;
Lytras, Theodore ;
Nikolopoulos, Georgios K. ;
Peyrin-Biroulet, Laurent ;
Danese, Silvio .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2016, 14 (10) :1385-+
[5]   Long-term Outcome of Treatment with Infliximab in Pediatric-onset Crohn's Disease: A Population-Based Study [J].
Crombe, Valerie ;
Salleron, Julia ;
Savoye, Guillaume ;
Dupas, Jean-Louis ;
Vernier-Massouille, Gwenola ;
Lerebours, Eric ;
Cortot, Antoine ;
Merle, Veronique ;
Vasseur, Francis ;
Turck, Dominique ;
Gower-Rousseau, Corinne ;
Lemann, Marc ;
Colombel, Jean-Frederic ;
Duhamel, Alain .
INFLAMMATORY BOWEL DISEASES, 2011, 17 (10) :2144-2152
[6]  
Danielson E., 2011, CISC VIS NETW IND GL
[7]   The duration of effect of infliximab maintenance treatment in paediatric Crohn's disease is limited [J].
de Bie, C. I. ;
Hummel, T. Z. ;
Kindermann, A. ;
Kokke, F. T. M. ;
Damen, G. M. ;
Kneepkens, C. M. F. ;
van Rheenen, P. F. ;
Schweizer, J. J. ;
Hoekstra, J. H. ;
Norbruis, O. F. ;
Ten, W. E. Tjon A. ;
Vreugdenhil, A. C. ;
Deckers-Kocken, J. M. ;
Gijsbers, C. F. M. ;
Escher, J. C. ;
de Ridder, L. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 33 (02) :243-250
[8]  
Deepak P, 2013, J GASTROINTEST LIVER, V22, P269
[9]   Common Infections in Patients Prescribed Systemic Glucocorticoids in Primary Care: A Population-Based Cohort Study [J].
Fardet, Laurence ;
Petersen, Irene ;
Nazareth, Irwin .
PLOS MEDICINE, 2016, 13 (05)
[10]  
Food and Drug Administration, 2018, INF HEALTHC PROF CIM